Pfizer celebrates a new FDA approval as the Xalkori franchise slowly winds down

John Carroll

Editor & Founder

Sales of Pfizer’s Xalkori may be slipping as new drugs squeeze the oncology market, but the pharma giant hasn’t lost its appetite for new indications …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer celebrates a new FDA approval as the Xalkori franchise slowly winds down

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Pfiz­er cel­e­brates a new FDA ap­proval as the Xalko­ri fran­chise slow­ly winds down

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pfizer celebrates a new FDA approval as the Xalkori franchise slowly winds down